Cutting‐edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The approval process for antibody biosimilars relies primarily on comprehensive analytical data to establish comparability and high similarity with the originator. Mass spectrometry (MS) in combination with liquid chromatography (LC) and electrophoretic methods are the corner stone for comparability and biosimilarity evaluation. In this special feature we report head‐to‐head comparison of trastuzumab and cetuximab with corresponding biosimilar and biobetter candidates based on cutting‐edge mass spectrometry techniques such as native MS and ion‐mobility MS at different levels (top, middle and bottom). In addition, we discuss the advantages and the limitations of sample preparation and enzymatic digestion, middle‐up and ‐down strategies and the use of hydrogen/deuterium exchange followed by MS (HDX‐MS). Last but not least, emerging separation methods combined to MS such as capillary zone electrophoresis‐tandem MS (CESI‐MS/MS), electron transfer dissociation (ETD), top down‐sequencing (TDS) and high‐resolution MS (HR‐MS) that complete the panel of state‐of‐the‐art MS‐based options for comparability and biosimilarity evaluation are presented. Copyright © 2015 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074943 · Cited by 1,521
Glycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829
Wei, H., Mo, J., Tao, L., Russell, R. J., Tymiak, A. A., Chen, G., Iacob, R. E., & Engen, J. R. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.07.019 · Cited by 208
Gahoual, R., Burr, A., Busnel, J.-M., Kuhn, L., Hammann, P., Beck, A., François, Y.-N., & Leize-Wagner, E. (2013) · mAbs · doi:10.4161/mabs.23995 · Cited by 90
Self-citation
Cited by
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Self-citationGlycan analysis of therapeutic glycoproteins
Zhang, L., Luo, S., & Zhang, B. (2016) · mAbs · doi:10.1080/19420862.2015.1117719 · Cited by 207
Recent advances in CE‐MS coupling: Instrumentation, methodology, and applications
Týčová, A., Ledvina, V., & Klepárník, K. (2017) · ELECTROPHORESIS · doi:10.1002/elps.201600366 · Cited by 99
Chen, B., Lin, Z., Alpert, A. J., Fu, C., Zhang, Q., Pritts, W. A., & Ge, Y. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b01865 · Cited by 82
Jin, Y., Lin, Z., Xu, Q., Fu, C., Zhang, Z., Zhang, Q., Pritts, W. A., & Ge, Y. (2019) · mAbs · doi:10.1080/19420862.2018.1525253 · Cited by 68
Metadata
- Authors
- Beck, A., Debaene, F., Diemer, H., Wagner‐Rousset, E., Colas, O., Dorsselaer, A. V., & Cianférani, S.
- Venue
- Journal of Mass Spectrometry
- Publisher
- Wiley
- Published
- 2015-02
- Volume
- 50
- Issue
- 2
- Pages
- 285-297
- ISSN
- 1076-5174 (ISSN-L)
- 1096-9888
- OpenAlex
- W2094580354
- Cited by
- 123
- References
- 4
- FWCI
- 8.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.